Policy & Regulation
Vifor Pharma meets primary endpoint in phase II Amber study of Veltassa
14 May 2019 -

Switzerland-based Vifor Pharma has met its primary endpoint in a phase II Amber study of its chronic kidney disease drug Veltassa (patiromer), it was reported yesterday.

The study has indicated that a significantly higher proportion of patients with resistant hypertension and chronic kidney disease taking Veltassa remained on spironolactone therapy compared to patients taking placebo at week 12.

The product was demonstrated to enable persistent use of spironolactone by controlling blood potassium levels. According to the company, the safety results are consistent with existing Veltassa data, with no new safety issues identified.

The product is a sodium-free potassium binder in powder form for the treatment of hyperkalaemia.